Skip to main content

Table 3 Serious bleeding and mortality rates in DrotAA-treated adults by baseline disease severity

From: Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies

Period and type of event

No PF, MEN, or MD N = 3,088

PF, MEN, or MD N = 1371

28-day mortality

  

   APACHE II

  

≥ 25

35.3 (433/1,227)

22.5 (11/49)

<25

19.1 (355/1,861)

12.5 (11/88)

   Number of organ failures

  

≥ 2

27.3 (693/2,538)

17.8 (18/101)

<2

17.3 (95/550)

11.1 (4/36)

SBEs during infusion

  

   APACHE II

  

≥ 25

3.7 (45/1,227)

4.1 (2/49)

<25

3.0 (55/1,861)

3.4 (3/88)

   Number of organ failures

  

≥ 2

3.4 (85/2,538)

4.0 (4/101)

<2

2.7 (15/550)

2.8 (1/36)

SBEs, 28-day

  

   APACHE II

  

≥ 25

6.2 (76/1,227)

6.1 (3/49)

<25

5.5 (102/1,861)

4.6 (4/88)

   Number of organ failures

  

≥ 2

6.0 (151/2,538)

5.0 (5/101)

<2

4.9 (27/550)

5.6 (2/36)

  1. 1Baseline APACHE II and baseline organ dysfunction data available for 137 patients (not collected for the 26 DrotAA-treated adults from the compassionate-use open-label EVAS trial. APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, drotrecogin alfa (activated); MD, meningococcal disease; MEN, meningitis; PF, purpura fulminans; SBE, serious bleeding event.
Back to article page

Critical Care

ISSN: 1364-8535